Search 

healthcare VC

2nd market PE,
about 300M RMB total value,
mainly focus on A-share market and startup on H-share market,
concentrating on high-speed developing industrials especially in Healthcare, including Big Biopharma/Superior Biotech companies.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. An IND was filed with favorable responses of communication from FDA were received in 2018 and 2020. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in Q2 2021. Additional products are in encapsulation feasibility studies. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy. On the same platform, additional active drugs with solubility and / or acute toxicity issues were successfully formulated to greatly improve delivery efficacy and safety.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 20 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. Co-founder and CSO Dr. Jun Li has many years of experience in innovative drug delivery system. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

Zhongyuan Yuzi is a provincial investment company and a province-managed state-owned corporation, the establishment of which is approved by Henan provincial government, with the function of serving the strategy and market operation and the role in safeguarding the investment of provincial infrastructure projects,cultivating and guiding the strategic emerging industries, leading and inciting the social investments.

Currently, we are looking for leading pharmaceutical companies as long-term financial or strategic investment partnerships.

河南省骨干企业。先后发起设立了3000亿元规模的河南省新型城镇化发展基金、1000亿元规模的“一带一路（河南）发展基金”、 1000亿元规模的全省现代服务业基金、50亿元规模的PPP开发性基金。

截至2019年12月底，豫资控股集团注册资金100亿元，合并总资产2734.9亿，净资产845.57亿。豫资控股集团子公司及孙公司（并表子公司）共计67家，其中二级子公司11家，三级子公司56家。国内评级AAA、国际评级A2。

四川创新发展投资管理有限公司（以下简称“川创投”）是一家主要从事股权投资及管理的专业机构,专注投资于自主创新高新技术企业、新兴产业企业和转型升级企业,投资范围涵盖生物医药、高端智能制造、TMT等重点行业领域。
川创投目前已承接管理了由四川省政府主导设立的四川省创新创业投资引导基金、四川省科技成果转化投资基金和四川省高层次人才创新创业投资基金等3支省级基金,在四川省全创区、China（绵阳）科技城、四川省自贸区和川南经济区先后布局6支区域子基金,并联合国内一线投资机构发起设立11支行业子基金,管理资本规模近100亿元,已初步形成深耕四川、覆盖全国的投资和服务网络。

康弘是一家致力于中药、化药和生物药研发、生产、销售及售后服务的大型医药集团。

专注于儿科品种

薄荷天使基金